Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties.

[1]  T. Beiert,et al.  Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties. , 2017, Biochemical and biophysical research communications.

[2]  Xiaoping Zhou,et al.  Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure. , 2017, Biological & pharmaceutical bulletin.

[3]  Anindita Das,et al.  Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism , 2017, Cardiovascular research.

[4]  Hong-jun Zhu,et al.  Effects of relaxin on cardiac fibrosis, apoptosis, and tachyarrhythmia in rats with myocardial infarction. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  T. Beiert,et al.  Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice. , 2016, Atherosclerosis.

[6]  C. Leo,et al.  Serelaxin: A Novel Therapeutic for Vascular Diseases. , 2016, Trends in pharmacological sciences.

[7]  G. Salama,et al.  Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels. , 2016, Heart rhythm.

[8]  N. Frangogiannis,et al.  Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. , 2016, Translational research : the journal of laboratory and clinical medicine.

[9]  J. Holmes,et al.  Physiological Implications of Myocardial Scar Structure. , 2015, Comprehensive Physiology.

[10]  Lx Wang,et al.  Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway , 2015, Drug design, development and therapy.

[11]  R. Bathgate,et al.  Serelaxin‐mediated signal transduction in human vascular cells: bell‐shaped concentration–response curves reflect differential coupling to G proteins , 2015, British journal of pharmacology.

[12]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[13]  S. Royce,et al.  Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease , 2014, Hypertension.

[14]  Philipp Sasse,et al.  Optogenetic activation of Gq signalling modulates pacemaker activity of cardiomyocytes. , 2014, Cardiovascular research.

[15]  K. Willecke,et al.  The Connexin40A96S mutation from a patient with atrial fibrillation causes decreased atrial conduction velocities and sustained episodes of induced atrial fibrillation in mice. , 2013, Journal of molecular and cellular cardiology.

[16]  Raisa E Jones,et al.  Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1 , 2013, Nature Communications.

[17]  Lei Yang,et al.  Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts , 2013, Circulation research.

[18]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[19]  Begoña Benito,et al.  Ventricular tachycardia in coronary artery disease. , 2012, Revista espanola de cardiologia.

[20]  M. Josephson,et al.  Ventricular Tachycardia in Coronary Artery Disease , 2012 .

[21]  S. Verheule,et al.  Cardiac electrophysiology in mice: a matter of size , 2012, Front. Physio..

[22]  L. Formigli,et al.  Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration , 2012, Journal of cellular and molecular medicine.

[23]  S. Yamamoto,et al.  Relaxin Modulates Proinflammatory Cytokine Secretion from Human Decidual Macrophages1 , 2011, Biology of reproduction.

[24]  Jacques M. T. de Bakker,et al.  Fibrosis and Cardiac Arrhythmias , 2011 .

[25]  Xiao-Ming Gao,et al.  Relaxin remodels fibrotic healing following myocardial infarction , 2011, Laboratory Investigation.

[26]  M. Metra,et al.  Relaxin: Review of Biology and Potential Role in Treating Heart Failure , 2010, Current heart failure reports.

[27]  S. Hazen,et al.  Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation , 2010, Nature Medicine.

[28]  Ross A. D. Bathgate,et al.  Cardiovascular effects of relaxin: from basic science to clinical therapy , 2010, Nature Reviews Cardiology.

[29]  L. Formigli,et al.  Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. , 2009, Journal of molecular and cellular cardiology.

[30]  E. Masini,et al.  Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. , 2008, Pharmacological research.

[31]  Guy Salama,et al.  Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia , 2007, Nature.

[32]  L. Formigli,et al.  Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling , 2007, Journal of cellular and molecular medicine.

[33]  Randall J. Lee,et al.  Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. , 2007, Journal of applied physiology.

[34]  Ralf Kettenhofen,et al.  Engraftment of engineered ES cell–derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium , 2006, The Journal of experimental medicine.

[35]  D. Duncker,et al.  A novel model of cryoinjury-induced myocardial infarction in the mouse: a comparison with coronary artery ligation. , 2005, American journal of physiology. Heart and circulatory physiology.

[36]  E. Masini,et al.  ©2005 FASEB The FASEB Journal express article 10.1096/fj.04-3664fje. Published online July 11, 2005. , 2022 .

[37]  Xiaojun Du,et al.  Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats , 2005, Hypertension.

[38]  J. Mak,et al.  Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. , 2004, Endocrinology.

[39]  K. Gauvreau,et al.  Implications of ventricular arrhythmia vulnerability during murine electrophysiology studies. , 2003, Physiological genomics.

[40]  L. Parry,et al.  Relaxin deficiency in mice is associated with an age‐related progression of pulmonary fibrosis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[42]  C. Antzelevitch.  Basic mechanisms of reentrant arrhythmias. , 2001, Current opinion in cardiology.

[43]  R. Watson,et al.  Age-related left ventricular function in the mouse: analysis based on in vivo pressure-volume relationships. , 1999, American journal of physiology. Heart and circulatory physiology.

[44]  E. Masini,et al.  Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. , 1998, The American journal of pathology.

[45]  E. Masini,et al.  Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. , 1997, Endocrinology.

[46]  E. Piedras-Rentería,et al.  Effects of relaxin on rat atrial myocytes. I. Inhibition of I(to) via PKA-dependent phosphorylation. , 1997, The American journal of physiology.

[47]  W. Giles,et al.  Relaxin increases heart rate by modulating calcium current in cardiac pacemaker cells. , 1994, Circulation research.